---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-002892"
form_type: "8-K"
ticker: "DYN"
cik: "0001818794"
company_name: "Dyne Therapeutics, Inc."
filed_at: "2024-01-05T23:59:59+00:00"
generated_at: "2026-06-07T03:18:30.486967+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Dyne Therapeutics prices $300M public offering of 17.15M shares at $17.50/share

## Summary
- Gross proceeds ~$300.1M from 17,150,000 shares; net proceeds ~$281.6M after discounts and expenses.
- Underwriters have 30-day option for up to 2,572,500 additional shares; if exercised, net ~$323.9M.
- Proceeds plus existing cash expected to fund operations through 2025.
- Offering led by Morgan Stanley, J.P. Morgan, Jefferies, Stifel; expected to close January 9, 2024.
- Shares sold by Dyne; no selling stockholders participating.

## SEC filing metadata
- accession: 0001193125-24-002892
- form_type: 8-K
- ticker: DYN
- cik: 0001818794
- company_name: Dyne Therapeutics, Inc.
- filed_at: 2024-01-05T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818794/000119312524002892/0001193125-24-002892-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818794/000119312524002892/d110504d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-002892
- JSON: https://secwatch.observer/filing/0001193125-24-002892.json
- Plain text: https://secwatch.observer/filing/0001193125-24-002892.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.